Figure 3.

The median survival of patients who received first-line EGFR-TKI therapy and salvage chemotherapy after failure of first-line EGFR-TKI treatment. (A): A total of 330 patients received first-line EGFR-TKI therapy. The median survival was significantly longer for the younger patients than for the older patients (median survival, 26.5 vs. 21.3 months; p = .014). (B): The median survival was longer for the younger patients than for the older patients receiving second-line salvage chemotherapy (18.2 vs. 10.9 months; p = .002). (C): The overall survival (OS) was longer in the younger group than in the older group with platinum-based chemotherapy (18.8 vs. 11.1 months; p = .004). (D): The OS was longer in the younger group than in the older group when receiving combination therapy (18.8 vs. 11.1 months; p = .003). (E): No significant difference was found in the median survival between the 2 age groups that received pemetrexed-based therapy (14.4 vs. 18.2 months; p = .162).

Abbreviation: EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor.